$1.06
7.83% yesterday
Nasdaq, Nov 15, 10:02 pm CET
ISIN
US6904691010
Symbol
OVID
Sector
Industry

Ovid Therapeutics Inc. Stock price

$1.06
-0.09 7.83% 1M
-2.26 68.07% 6M
-2.16 67.08% YTD
-2.30 68.45% 1Y
-2.58 70.88% 3Y
-1.53 59.07% 5Y
-11.19 91.35% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.09 7.83%
ISIN
US6904691010
Symbol
OVID
Sector
Industry

Key metrics

Market capitalization $75.27m
Enterprise Value $28.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 45.41
P/S ratio (TTM) P/S ratio 119.48
P/B ratio (TTM) P/B ratio 0.99
Revenue growth (TTM) Revenue growth 113.07%
Revenue (TTM) Revenue $630.00k
EBIT (operating result TTM) EBIT $-69.35m
Free Cash Flow (TTM) Free Cash Flow $-57.92m
Cash position $62.71m
EPS (TTM) EPS $-0.46
P/E forward negative
P/S forward 126.56
EV/Sales forward 54.21
Short interest 1.04%
Show more

Is Ovid Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Ovid Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Ovid Therapeutics Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Ovid Therapeutics Inc. forecast:

Buy
78%
Hold
22%

Financial data from Ovid Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.63 0.63
110% 110%
100%
- Direct Costs 0.85 0.85
48% 48%
135%
-0.22 -0.22
84% 84%
-35%
- Selling and Administrative Expenses 27 27
0% 0%
4,319%
- Research and Development Expense 41 41
78% 78%
6,519%
-68 -68
33% 33%
-10,871%
- Depreciation and Amortization 0.85 0.85
48% 48%
135%
EBIT (Operating Income) EBIT -69 -69
30% 30%
-11,008%
Net Profit -33 -33
33% 33%
-5,159%

In millions USD.

Don't miss a Thing! We will send you all news about Ovid Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ovid Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
2 months ago
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pi...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024.
Neutral
GlobeNewsWire
4 months ago
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in August:
More Ovid Therapeutics Inc. News

Company Profile

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Head office United States
CEO Jeremy Levin
Employees 40
Founded 2014
Website www.ovidrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today